BPTH - Bio-Path Holdings, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.6273
-0.3327 (-34.66%)
As of 9:36AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close0.9600
Open0.7000
Bid0.5000 x 800
Ask0.7000 x 1200
Day's Range0.6273 - 0.7000
52 Week Range0.6273 - 5.9000
Volume10,178
Avg. Volume23,856
Market Cap7.114M
Beta2.27
PE Ratio (TTM)N/A
EPS (TTM)-0.7560
Earnings DateNov 7, 2018 - Nov 12, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est15.00
Trade prices are not sourced from all markets
  • GlobeNewswire3 hours ago

    Bio-Path Holdings, Inc. Announces $1.5 Million Registered Direct Offering

    Bio-Path will issue to the investors warrants to purchase up to 2,261,538 shares of common stock, which represents 100% of the number of shares of common stock issued in the registered direct offering, with an exercise price $0.96 per share and exercise period commencing six (6) months following the issuance date and a term of five and one-half (5.5) years. Bio-Path currently intends to use the net proceeds from the offerings for working capital and general corporate purposes.

  • GlobeNewswire23 days ago

    Bio-Path Holdings to Present at the H.C. Wainwright 20th Annual Global Investment Conference

    HOUSTON, Aug. 29, 2018-- Bio-Path Holdings, Inc.,, a biotechnology company leveraging its proprietary DNAbilize ® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid ...

  • GlobeNewswire25 days ago

    Bio-Path Holdings Announces First Patient Dosed in Expansion of Phase 2 Trial of Prexigebersen in Acute Myeloid Leukemia

    Bio-Path Holdings, Inc., (BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced it has commenced Stage 2 of the company’s Phase 2 trial of prexigebersen in acute myeloid leukemia. “We are delighted to announce the expansion of our ongoing Phase 2 clinical trial of prexigebersen for the treatment of acute myeloid leukemia using a dosing schedule that administers a greater amount of prexigebersen to the patient prior to commencing LDAC dosing than in the first part of the trial.

  • GlobeNewswirelast month

    Bio-Path Holdings Appoints Dr. Jason B. Fleming to Scientific Advisory Board

    Bio-Path Holdings, Inc., (BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced the appointment of Jason B. Fleming, M.D., F.A.C.S., to its Scientific Advisory Board (SAB). “We are thrilled to welcome Dr. Fleming to our scientific advisory board. As a leader in the treatment of gastrointestinal cancers, Dr. Fleming will be able to offer substantial insight as we seek to advance our lead drug candidate prexigebersen and our third drug candidate, BP1003, towards the clinic for the treatment of pancreatic cancer,” said Peter Nielsen, President and Chief Executive Officer of Bio-Path.

  • Associated Presslast month

    Bio-Path: 2Q Earnings Snapshot

    The Bellaire, Texas-based company said it had a loss of 15 cents per share. The company's shares closed at $1.41. A year ago, they were trading at $3. _____ This story was generated by Automated Insights ...

  • GlobeNewswirelast month

    Bio-Path Holdings Reports Second Quarter 2018 Financial Results

    Bio-Path Holdings, Inc., (BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced its financial results for the second quarter ended June 30, 2018 and provided an update on recent corporate developments. “During the second quarter we have continued to advance our corporate mission to develop RNAi nanoparticle drugs for cancer patients with high unmet medical need. Earlier studies showed 47% of evaluable patients demonstrated some degree of response to prexigebersen in combination with LDAC in this patient population, which is supportive of our Phase 2 clinical development program.

  • ACCESSWIRElast month

    Bio-Path Holdings, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 15, 2018 / Bio-Path Holdings, Inc. (NASDAQ: BPTH ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 15, 2018 at 8:30 AM Eastern ...

  • GlobeNewswirelast month

    Bio-Path Holdings to Announce Second Quarter 2018 Financial Results on August 15, 2018

    HOUSTON, Aug. 08, 2018-- Bio-Path Holdings, Inc.,, a biotechnology company leveraging its proprietary DNAbilize ® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid ...

  • ACCESSWIRE3 months ago

    Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (NASDAQ: BPTH)

    DALLAS, TX / ACCESSWIRE / June 26, 2018 / Bio-Path Holdings, Inc. ("Bio-Path") (NASDAQ: BPTH): COMPANY DESCRIPTION Bio-Path Holdings, Inc. (Bio-Path) is a clinical-stage biotechnology company ...

  • With A -19.42% Earnings Drop, Is Bio-Path Holdings Inc’s (NASDAQ:BPTH) A Concern?
    Simply Wall St.4 months ago

    With A -19.42% Earnings Drop, Is Bio-Path Holdings Inc’s (NASDAQ:BPTH) A Concern?

    For long-term investors, assessing earnings trend over time and against industry benchmarks is more beneficial than examining a single earnings announcement at a point in time. Investors may find myRead More...

  • Associated Press4 months ago

    Bio-Path: 1Q Earnings Snapshot

    The Bellaire, Texas-based company said it had a loss of 17 cents per share. The company's shares closed at $1.76. A year ago, they were trading at $5.31. _____ This story was generated by Automated Insights ...

  • ACCESSWIRE5 months ago

    Wired News – EMA Completed Validation of MAA for Aradigm’s Linhaliq in Non-Cystic Fibrosis Bronchiectasis

    Stock Monitor: Bio-Path Holdings Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 09, 2018 / Active-Investors.com has just released a free research report on Aradigm Corp. (NASDAQ: ARDM ). If you ...

  • Bio-Path Leukemia Combo Study Shows Positive Early Data
    Zacks6 months ago

    Bio-Path Leukemia Combo Study Shows Positive Early Data

    Bio-Path (BPTH) announces positive interim data from phase II study of its lead pipeline candidate ??? prexigebersen ??? in combination with low-dose cytarabine (LDAC) for leukemia patients.

  • Bio-Path: Why the Biotech Penny Stock Is Skyrocketing Today
    InvestorPlace6 months ago

    Bio-Path: Why the Biotech Penny Stock Is Skyrocketing Today

    The other bit of good news for BPTH stock today was financial results for its fiscal full year of 2017. During the year, the company reported a net loss of $8.1 million, or 80 cents per share. This is a wider net loss than the $6.8 million, or 73 cents per share from the year prior.

  • Benzinga6 months ago

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Long Blockchain Corp (NASDAQ: LBCC ) stock gained ...

  • ACCESSWIRE6 months ago

    Bio-Path Holdings, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / April 3, 2018 / Bio-Path Holdings, Inc. (NASDAQ: BPTH ) will be discussing their earnings results in their Q4 Earnings Call to be held on April 3, 2018 at 8:30 AM Eastern Time. ...